SCHEMBL3003095

SCHEMBL3003095

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(C)cc4)CC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
MAPT P10636 5/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPK1 P28482 4/20 0.48
LMNA P02545 4/20 0.48
MEN1 O00255 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
TSHR P16473 1/20 0.43
GBA1 P04062 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019911 0.93 SMN1; SMN2 (0.63) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3015007 0.92 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3011619 0.91 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3014390 0.91 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3002006 0.91 KMT2A (0.47) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3002010 0.91 MAPT (0.53) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3015149 0.91 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3012568 0.89 KMT2A (0.46) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3006770 0.89 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL3003574 0.88 RAB9A (0.58) SMN1; SMN2RAB9ANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.